Riyadh - Sharikat Mubasher: Gulf Pharmaceutical Industries (Julphar), one of the leading pharmaceutical companies in the UAE and the GCC region, intends to establish a new pharma and biotech manufacturing facility in Saudi Arabia with investments worth SAR 300 million.

In a statement, Julphar revealed that the state-of-the-art facility will include complex biologics, sterile and general formulation drug manufacturing, and will follow the highest quality standards, fulfilling SFDA, EMA, and USFDA guidelines.

Julphar is set to start implementing the project during the first quarter (Q1) of 2025. After completing the facility, the company will introduce a range of complex biologics and other medications.

This project comes as part of Julphar’s growth strategy in key GCC markets and complements its continued investment initiatives in advanced manufacturing capabilities.